Pacemaker and defibrillator combination therapy for recurrent ventricular tachycardia

MARTIN MASTERNON, MB, BCH; SERGIO L. PINSKI, MD; BRUCE WILKOFF, MD; TONY W. SIMMONS, MD; VICTOR A. MORANT, MD; LEONARD R. GOLDING, MB, BS; LON W. CASTLE, MD; JAMES D. MALONEY, MD

The judicious use of antitachycardia pacemakers can enhance the benefits of automatic implantable cardioverter defibrillators in certain patients. Both devices were implanted in 10 highly selected patients with drug-refractory pace-terminable sustained ventricular tachycardia. During the observation period of 8 ± 4.8 months, the automatic pacemakers detected 1,542 episodes of ventricular tachycardia and appropriately managed 1,373. The automatic implantable defibrillator was activated at least once in every patient; on two documented occasions, the defibrillator discharged because the automatic pacemaker accelerated the tachycardia. Concomitant antiarrhythmic drugs could be reduced but not withdrawn. With meticulous device programming and testing, the two systems in combination can work synergistically to manage malignant ventricular arrhythmias in carefully selected patients.

INDEX TERMS: CARDIAC PACING, ARTIFICIAL; TACHYCARDIA

The prognosis is guarded for patients with atherosclerotic heart disease, left ventricular dysfunction, and monomorphic sustained ventricular tachycardia (VT$_S$) that is refractory to medical therapy. The 1-year mortality rate is 28%; the 1-year sudden death incidence is 17%.

The automatic implantable cardioverter defibrillator (AICD) reduces the yearly incidence of sudden cardiac death in this patient population to approximately 2%, and total mortality at 5 years is about 30%.

The major drawback of antitachycardia pacing is VT$_S$ acceleration, which occurred in 43% of patients in one series.

Automatic antitachycardia pacemakers (ATPs) have had short-term benefits in a few carefully selected patients with drug-refractory VT$_S$ but the long-term benefit of this therapy in the absence of defibrillation backup is questionable. The use of the two devices in combination is one way to overcome these limitations.

Beginning in August 1986, we implanted independent automatic ATPs in combination with AICDs in carefully selected patients. The selected patients had both slow and rapid VT$_S$ or ventricular fibrillation that
RECURRENT VENTRICULAR TACHYCARDIA • MASTERTON AND ASSOCIATES

TABLE 1
PROTOCOL FOR DEVICE INTERACTION TESTING

1. Programming pacemakers in bipolar mode.
2. Reconfirming the optimal pacing protocol for VT termination.
3. Ruling out double-counting.
4. Selecting algorithm for rapid VT sensing and termination without AICD triggering.
5. Testing of both devices together during induced VT.
6. Ruling out of AICD inhibition by pacemaker pulses during induced ventricular fibrillation.

was refractory to drug therapy and were not considered suitable candidates for surgical or catheter ablation of their VTs.

This report is a descriptive analysis of our clinical investigation. Our objectives were to: (1) evaluate methods for testing device compatibility; (2) determine whether the ATP could terminate both slow and rapid VTs, thus reducing the requirement for AICD discharges; (3) determine whether combined device therapy in patients previously considered poor candidates for the AICD could eliminate or significantly reduce the need for concomitant antiarrhythmic drug therapy; and (4) determine the efficacy and feasibility of combined device therapy to manage malignant ventricular arrhythmias.

PATIENT POPULATION

AICDs were implanted in 105 patients (mean age, 57 years) between May 1984 and December 1987. These patients had been referred to our institution because of hypertensive VTs or sudden cardiac death that was refractory to conventional antiarrhythmic drug therapy.

Despite continued drug therapy, 17 patients in this group had frequent, symptomatic, recurrent VTs at a mean rate of 130 bpm, which is below the tachycardia detection rate (mean, 154 bpm) of the nonprogrammable AICD. The use of an ATP and the AICD was considered as a possible treatment option for these patients.

Ten of the 17 patients had pace-terminable VTs and were identified as candidates for combination ATP/AICD implantation. The other seven patients, whose VTs were not reliably pace-terminable, were excluded from consideration for combined device therapy.

Clinical characteristics of the study group

All 10 male patients (mean age 61 ± 8 years) underwent biochemical profiles, electrocardiography (ECG), multiple 24-hour ECG monitoring, coronary angiography with left ventriculography, and cardiac electrophysiologic assessment.

All patients had coronary artery disease with previous myocardial infarctions. Two-vessel disease was present in six patients and three-vessel disease in four. Six patients had had previous coronary bypass surgery and one had had previous antiarrhythmic surgery. Six patients were in New York Heart Association functional class II for heart failure and four were in class III. The mean left ventricular ejection fraction was 32.4 ± 11%.

Arrhythmia characteristics

The patients in this group had responded poorly to a mean of 7.8 different antiarrhythmic regimens. Among the 10 patients, there were 4.3 hospitalizations requiring 6.2 ± 2.6 external cardioversions for spontaneous VT.

All 10 patients had VTs induced during cardiac electrophysiologic study while they were drug-free, and on repeat testing during medication with a variety of conventional and investigational antiarrhythmic agents; all continued to have spontaneous VTs despite therapy. The mean VTs rate was 195 bpm without drugs, and 130 bpm during drug therapy.

METHODS

ATPs were implanted in the 10 patients. The Orthocor II 284A (Cordis Pacing Systems, Miami, Fla) ATP, which was released in July 1985 as a clinical investigational device for the treatment of VTs, was implanted in four patients beginning in August 1986. The Intertach ATP (Intermedics Inc., Freeport, Tex) was released for clinical investigation in August 1986 to treat VTs and was implanted in the subsequent six patients.

Devices

The characteristics of the Automatic Implantable Cardioverter Defibrillator (AICD [Cardiac Pacemakers Inc., St. Paul, MN 55164]) have been described previously.22

Both ATP devices are single-chamber, multiprogrammable, and bipolar. They are capable of detecting, cataloguing, and treating tachycardias, and can also prevent bradycardia below a programmable rate.

Both pacemakers detect, as "pathologic tachycardia," any ventricular rhythm above a programmable rate (100–220 bpm, Orthocor; 94–226 bpm, Intertach) that persists for a programmable number of intervals. In the Intertach ATP, this basic detection algorithm has been made more specific with the addition of three programmable criteria: (1) suddenness of onset of tachycar-
(2) rate variability, or the maximum allowed variability between R-R intervals that define a rhythm as VT, which helps to distinguish atrial fibrillation from VT; and (3) sustained high rate, which detects tachycardia that persists above the threshold rate for up to 250 programmable intervals. The third variable is used only in conjunction with the first and second and can override them both. This may reveal a persistent VT that does not meet the other two criteria, but it does so at the cost of decreased specificity. With this combination of criteria, nine different detection algorithms are possible.

When a tachycardia is detected, termination is attempted by the pacemaker delivering one, two, or three critically timed extrastimuli, or a burst of extrastimuli (Orthocor, up to 30; Intertach, up to 250). These are programmable either as a percentage of the tachycardia cycle length (Intertach) or at fixed intervals after the last sensed event (both Orthocor and Intertach). The pacemaker can be programmed to scan progressively shorter intervals if the first sequence does not effectively terminate the tachycardia. Successful sequences are stored in the device's memory and used first if the tachycardia recurs. The Intertach has primary and secondary response modalities that can be programmed independently.

Both devices have extensive memory capacity for

FIGURE 1. Short time frame available for successful combined device therapy. A: Induced ventricular tachycardia and simultaneous phonographic recording of the implantable cardioverter-defibrillator demonstrates the 5 to 5.5 seconds required for tachycardia recognition by the AICD (arrow, AICD discharge). B: Holter recording of spontaneous ventricular tachycardia with automatic detection and termination in less than 5 seconds by the antitachycardia pacemaker; event did not trigger the AICD.
FIGURE 2. ATP and AICD testing to exclude life-threatening AICD inhibition. VOO pacing at maximum energy output during induced ventricular fibrillation (worst-case scenario) demonstrates absence of AICD inhibition.

TABLE 2

ORTHOCOR II DETECTION AND TERMINATION ALGORITHMS

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detection</td>
<td>Rate (bpm)</td>
<td>130</td>
<td>110</td>
<td>135</td>
</tr>
<tr>
<td>Number of intervals</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Termination</td>
<td>Automatic overdrive</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Number of pulses</td>
<td>7</td>
<td>3</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Overdrive constant (ms)*</td>
<td>40</td>
<td>100</td>
<td>40</td>
<td>60</td>
</tr>
<tr>
<td>Ramp between pulses (ms)</td>
<td>-23</td>
<td>-23</td>
<td>-8</td>
<td>-15</td>
</tr>
<tr>
<td>Maximum pace interval (ms)</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>Number of attempts</td>
<td>Infinite</td>
<td>Infinite</td>
<td>10</td>
<td>15</td>
</tr>
</tbody>
</table>

*Overdrive constant = interval in ms less than the ventricular tachycardia cycle length detected

storage of the tachycardia rate and the number of episodes. The Orthocor also records the duration. Noninvasive cardiac electrophysiologic stimulation can be performed using implanted devices by means of telemetry interaction with an external programmed stimulator.

Surgical procedures and device compatibility testing

The AICDs were implanted using general anesthesia. A bipolar endocardial lead was used in every case, placed as far as possible from the epicardial sensing leads (generally in the right ventricular apex).

A comprehensive protocol was followed in order to detect and avoid potentially deleterious device-to-device interactions (Table 1). This included:

1. Programming of the ATP to the bipolar mode.
2. Reconfirmation of the optimal pacing protocol for terminating VT. This was done by placing the AICD in the stand-by “electrophysiologic mode” and then inducing the patient’s VT on at least 10 occasions (range 10–16). VVT mode was frequently used during this step to help assess pacemaker sensing function.

3. To assure the absence of double counting, pacing was then initiated above the patient’s intrinsic heart rate at maximum energy output for the ATP. The sensing function of the AICD was then assessed with a Beepogram.23

4. The ATP detection and termination algorithm was then selected to ensure that the time frame encompassed for successful function would not exceed the time for tachycardia recognition by the AICD (ideally less than 5 seconds [Figures 1A and 1B]). The maximal heart rate response attained during previous symptom-limited exercise testing was also taken into account when selecting the tachycardia detection rate.

5. The simultaneous function of both activated devices was then assessed against induced VT. In all patients, the ATP terminated the VT on its first attempt without triggering the AICD.

6. Finally, to ensure that pacemaker pulses delivered during ventricular fibrillation would not be wrongly sensed as a normal rhythm by the AICD (due to its automatic gaining control), special testing was undertaken. The pacemakers were programmed to the VOO mode with maximum energy output and then ventricular fibrillation was induced. This “worst case scenario” did not interfere with normal AICD function, which sensed and terminated the induced fibrillation on its...
first attempt (mean 13.8 seconds) in all patients (Figure 2).

If deleterious interactions were detected during any of the testing steps, they were managed by repositioning the transvenous lead-electrode farther from the epicardial leads and repeating the testing sequence.

Since current AICDs are “committed devices” (once they are activated they always discharge), this assessment is critical to ensure that the ATP will detect and terminate VTs before AICD activation, sparing the patient a needless shock.

ATP tachycardia detection algorithms are compared in Tables 2 and 3. A composite chest/abdomen radiograph (Figure 3) shows both devices in place.

**Patient follow-up**

The 10 patients underwent monthly evaluations, including history, physical examination, check of AICD status, and telemetry of stored arrhythmia data from the memory of the ATPs. Ambulatory ECG monitoring was performed every 2 months.

**RESULTS**

**Mortality**

Five patients died during the observation period. Three of the deaths were sudden. One patient died suddenly 5 days after implantation. ECG monitoring disclosed four episodes of ventricular fibrillation in the minutes preceding his death. Three of these were treated successfully with AICD discharges. The ATP did not induce the arrhythmias or interfere with AICD function.

Two patients died suddenly at home. In one, who died after 11 months, total AICD battery depletion was noted when the device was explanted. In retrospect, this patient had premature battery depletion. His charge time 1 month before his death suggested the need for elective generator replacement. The other, who died after 10 months, had been restarted on amiodarone because of frequent AICD discharges for rapid VT. The reintroduction of amiodarone 2 weeks before his death may have contributed to his death by increasing an already high defibrillation threshold.

Finally, one patient died from hepatitis B at 2 months after implantation, and the other died of heart failure at 11 months.

**VTs termination**

Analysis of ATP memories showed that at 8 ± 4.8 months, the ATPs had detected 1,542 episodes of VTs.
nated prior to discharge. One AICD discharge was induced when an episode of sinus tachycardia triggered the ATP. The ATP discharge, in turn, induced VT which was terminated by the AICD (Figure 4). The patient's ATP was deactivated until his sinus rate response to exercise was controlled pharmacologically.

In the other 11 documented pacemaker treatments, VT was expeditiously detected and terminated without triggering the AICD (Figure IB).

Three patients who had toxic reactions to amiodarone (Figure 5) had antiarrhythmic drugs withdrawn and were treated solely with the devices. In two of these, it was necessary to restart drug therapy after a mean of 4 months to control the increased frequency of rapid VT requiring AICD discharges. The third patient died after 2 months from hepatitis B.

Subsequently, all patients were maintained on full antiarrhythmic drug therapy, although the combination of devices allowed low dosages and minimized the risk of drug toxicity.

Complications

During implantation of the first patient, his tined ATP lead dislodged at the time of an AICD discharge. Active fixation leads were implanted in subsequent patients.

The memory of the ATP disclosed that 10 of the AICD discharges were for episodes of VT that persisted for less than 6 to 8 seconds, but nevertheless activated the discharge of the committed AICD. Holter monitoring showed that in four patients, 11 episodes of slow VT remained undetected because their rates were below the programmed detection rate. This was managed by decreasing drug therapy and/or reprogramming of the detection algorithm. Three episodes of VT were detected but not terminated by the ATP; these patients responded then to a more aggressive termination algorithm. Two patients required pharmacologic blunting of their sinus rates with beta blockers for successful ATP function.

Three patients were intolerant to VVI pacing backup by their ATP (pacemaker syndrome). This was managed by reprogramming the lower rate or inactivating the antitachycardia backup function.

DISCUSSION

Patients with atherosclerotic heart disease, left ventricular dysfunction, and sustained monomorphic ventricular tachycardia represent a major therapeutic challenge, particularly when the tachycardia is resistant...
Evaluating device compatibility

Single- and dual-chamber pacing may interfere with normal AICD function, although with careful planning most interactions can be prevented. The important considerations are that the pacing electrodes be bipolar; that the rate-counting AICD sensing electrodes be bipolar and distanced as far as possible from the pacing electrode (ideally in the other ventricular chamber); and that pacing and sensing parameters be optimized. Specific testing is essential at the time of pacemaker implantation to ensure recognition of tachycardia by the AICD during possible loss of pacemaker inhibition; for example, a pacemaker pulse during ventricular fibrillation that is sensed falsely by the AICD as QRS would preclude a lifesaving AICD shock.

The pacemaker should be programmed to its asynchronous mode at maximum energy output; then, correct AICD function must be confirmed during induced ventricular fibrillation.

In this series, ATP function, VVI pacing mode, memory, and telemetry function were not adversely affected by AICD discharges in any patient.

Current tachycardia detection algorithms are suboptimal; ideally, the tachycardia rate threshold should be...
less than the slowest VTs rate and greater than the maximum exercise-induced heart rate with a moderate safety margin. If this is impossible to achieve, then pharmacologic adjustment of the sinus rate may be necessary. For example, in one patient, sinus tachycardia triggered his ATP, which activated his AICD. He required beta blocker therapy in addition to his usual antiarrhythmic therapy to control his sinus rate.

**ATP termination of rapid VTs**

As retrieved from the memory of the ATP, all patients in this series had VTs at rates ranging from 140 bpm to 190 bpm. In the absence of complete ECG documentation, we are unable to determine how many of these episodes were spontaneous or resulted from ATP-induced VTs acceleration, but in two episodes VTs acceleration was ECG-documented. The clinical impression is that the ATPs do not significantly reduce the number of AICD discharges for rapid VTs.

Pace-termination of rapid VTs in this patient group was largely unsuccessful at implantation of the devices, suggesting that termination of spontaneous, rapid VTs requires an AICD discharge.

The memory of the Orthocor II documented 10 AICD discharges for episodes of VT unlikely to have persisted to the time of the discharge. This observation demonstrates a limitation of the AICD: It fails to re-check if a tachycardia is still present just prior to discharge. Although ATP termination of slow VTs is well documented, the two documented episodes of AICD discharges induced by VTs acceleration is probably an underestimation. Further clarification of this issue will require careful scrutiny over a longer follow-up period with ECG monitoring.

Since both devices function independently, they may simultaneously attempt to terminate an episode of VT. This could cause the ATP pulse burst to induce further VT—a phenomenon that was observed in the laboratory during device testing.

**Limitations**

Both ATPs are single-chamber devices; if antibradycardia pacing is required, it will be in the ventricular demand mode, which will lead to atrioventricular asynchrony. This could significantly reduce cardiac output (as demonstrated by the development of the pacemaker syndrome in the three patients in this series). Although both ATPs are among the most sophisticated devices currently available, the tachycardia detection algorithm based on heart rate is a major limitation.

An improved algorithm might incorporate intracardiac electrograms and physiologic sensors. Both ATPs have extensive memory capability, but they lack the ECG documentation that is needed to assess rhythms.

As discussed, the two major limitations of the 1986–1990 AICD models are the lack of programmability and, especially, the inability to check if a tachycardia has terminated once capacitor charging commences.

**Feasibility of combined devices**

Drug-refractory VTs can be terminated by antitachycardia pacing without causing patient discomfort. However, even in patients with stable VTs, automatic ATPs should be implanted only in conjunction with the AICD. VTs stability over time is unpredictable. The AICD provides backup defibrillation for rapid or accelerated VTs and ventricular fibrillation. Furthermore, in the few patients who develop transient bradyarrhythmias after an AICD discharge, the ATP provides pacing backup.

The combined use of an ATP and the AICD is a feasible therapeutic approach for carefully selected patients who have both slow and rapid recurrent VTs. All patients in this series required concomitant pharmacologic therapy to reduce the frequency and rapidity of episodes. Nevertheless, the devices terminated potentially lethal arrhythmias a mean of 154 times per patient.

Antitachycardia pacing-defibrillator combination therapy may serve as a bridge to the "ideal tachyarrhythmia device," designed to provide tiered levels of therapy. These include antitachycardia discrete pulse therapy, low energy cardioversion therapy, and defibrillation backup, along with sophisticated tachycardia recognition algorithms, telemetered event recording to confirm rhythm before and after electronic therapy, and bradycardia backup.

Although these ideal goals are attainable, it is unlikely that they will be available in a practical and affordable package before the 21st century. Even then, careful medical selection based on need relative to cost of the most sophisticated devices will be required. These risk/benefit cost-effectiveness issues will have even more importance in less affluent areas of the world; therefore, use of combination antitachycardia pacing devices with implantable defibrillators will likely persist for the next two decades.

Careful patient selection and detailed system analysis to avoid adverse interactions between the two devices will continue to be the key to successful use of combined device therapy.
REFERENCES


